**Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges**

**Ms. Pranjali Namdevrao Bansod**

**Department of Pharmacology, Vidhyabharti College of Pharmacy, Camp Road CK Naidu Road Marg, Amravati, Maharashtra:444602**

**Mobile No: 7758056832**

**Co- Author: Dr Vivek Paithankar Sir**

**Corresponding author: Pranjali Namdevrao Bansod**

**Address of Corresponding author: Vidhyabharti College of Pharmacy, Camp Road CK Naidu Road Marg, Amravati, Maharashtra:444602**

**Corresponding author: pranjlibansod@gmail.com**

**Abstract:**  
Drug delivery systems play a critical role in determining the clinical pharmacology of therapeutic agents. This paper explores a comprehensive array of drug delivery approaches such as solubility and permeability enhancement, modified release, prodrug strategies, and targeted/localized delivery. Each method's principles, advantages, and limitations are discussed with a view toward improving therapeutic efficacy and minimizing adverse effects. Future trends and research directions are highlighted to guide innovative clinical applications.

Keywords: Drug Delivery, Clinical Pharmacology, Solubility Enhancement, Modified Release, Prodrug, Targeted Therapy

**INTRODUCTION**

Drug transport refers to numerous procedures for turning in a pharmaceutical compound inside the human frame to obtain and/or optimize the preferred healing effect(s), whilst minimizing its damaging impact(s) if viable [1,2,3] Pharmaceutical compounds include, however are not limited to, chemicals, peptides, antibodies, and vaccines, as well as genebased pills. Drug shipping systems can be categorised into exceptional classes primarily based at the path of administration. further to the conventional processes like oral, injectable, transdermal, inhalation, implant, suppository, ophthalmic, and otic dosage paperwork, novel drug shipping systems like focused transport and drug-device mixtures at the moment are attracting an increasing number of interests in drug development

when you consider that drug transport processes have been so broadly explored to address pharmacology-associated problems from some many special angles, it's far difficult to categorize them without a clear criterion. except prodrug method, drug transport approaches normally do not involve chemical modification of the active aspect. those tactics include solubilization, permeability enhancement, modified release (MR), and different unique drug transport mechanisms, inclusive of targeted shipping, reduced nearby irritation, and drug-tool aggregate. Prodrug delivery, which includes chemical amendment of the pharmacologically energetic moiety, is discussed in a separate section.

Drug shipping strategies do now not trade the fundamental pharmacodynamic properties of a pharmaceutical compound, but they may exchange its pharmacokinetic houses to impact its pharmacodynamic overall performance. For both drug improvement and next regulatory evaluation, a favoured drug goal product profile (DTPP) must be properly defined [4]. clinical pharmacology-related issues that can influence the preferred therapeutic results include, however aren't limited to, the subsequent:

1. Dose, dosing frequency, and dose changes

2. Pharmacokinetic profiles

3. neighbourhood drug irritation

4. patient compliance

5. Inter-patient version

among distinctive pharmacokinetic houses, location beneath the curve of awareness-time profile (AUC), maximum serum concentration (Cmax), time to reach Cmax (Tmax), and elimination half of-life (T1/2) are the four parameters which have been maximum usually evaluated and optimized in drug improvement and next regulatory evaluation. aimed toward maximizing therapeutic efficacy and minimizing side results, drug shipping tactics may be used to achieve the preferred AUC, Cmax, Tmax, and T1/2 by adjusting absorption, distribution, metabolism, and elimination (ADME) of a pharmaceutical compound [5,6].

further to poor aqueous solubility and occasional permeability, it is essential to say that pre systemic clearance is any other commonplace purpose for bad oral bioavailability. Orally administered drug may be prematurely cleared off the system because of hydrolysis inside the belly, enzymatic digestion in the gastric and small intestinal fluids, metabolism within the brush border of the gut wall, metabolism with the aid of microorganisms inside the colon, and metabolism inside the liver prior to getting into the systemic move (first skip impact), etc., gastrointestinal (GI) tract website online-specific transport methods, along with enteric coating, colonic transport, and gastric-retention device, or altered routes of administrations, which includes transdermal, intravenous (IV), buccal, inhalation, colon, suppository, can be used to deal with this issue of presystemic clearance to acquire the preferred bioavailability.

For positive capsules, localized drug exposure in place of systemic exposure is desired to be able to supply a high dose to the site of motion to limit or even keep away from systemic unfavourable impact(s). neighbourhoods drug exposure may be found out through applying the drug product directly to the site of action thru conventional nearby drug transport systems, such as topical, transdermal, ophthalmic, pulmonary, and intrathecal drug delivery systems. it's far worth noting that some drug shipping structures implemented domestically can also provide systemic exposure which might also or may not be proper. similar to however distinctive from nearby transport, cantered shipping is any other manner to obtain the intention of maximizing the nearby drug publicity and minimizing systemic aspect effect(s). As can be seen within the literature and drug product approval records, focused therapy has been attracting growing interest in oncology remedies, as it offers a way to triumph over the notorious systemic facet outcomes of traditional chemotherapy. in addition to designing chemical compounds with excessive selectivity and immunotherapy, drug shipping systems such as nanomedicines and antibody-drug conjugates (ADC) were successfully carried out for some marketed pills.

patient compliance is frequently part of the fulfilment. story of any properly drug product within the market. minimum side outcomes and ease of use are two fundamental approaches to promote affected person compliance. As stated above, drug shipping processes that assist to reduce side consequences, both systemically and regionally, in reality will improve patient compliance. different drug delivery procedures to in addition ease the use of a drug product are modified release strategies for decreased dosing frequencies and patient pleasant transport devices to facilitate self-administration [5,6]. thinking about such procedures is crucial as drug delivery systems are only powerful if (the) patients take them.

**Solubility Enhancement**

considering the display technique for lead compounds in drug discovery level, more and more drug applicants getting into improvement stage are water insoluble, mainly for oncology compounds. primarily based on drug aqueous solubility and permeability, drugs were labelled into four biopharmaceutical training [7–9]. For a drug product meant for injection, mainly for IV administration, reaching sufficient solubility at a physiological well-matched surroundings is required. For a drug product this is supposed for oral management, the aqueous solubility generally refers to drug solubility underneath the human GI tract pH which degrees from 1.0 to 7.4. To acquire enough oral bioavailability for a water insoluble pharmaceutical compound, improving dissolution of the compound in the human GI tract is commonly the point of interest at some stage in/of pharmaceutical improvement [10]. commonly used drug transport techniques for solubilizing tablets with terrible aqueous solubility are indexed as follows:

1. pH adjustment and salt formation

2. Co-solvent

3. Micelles (surfactants)

4. Microemulsions and emulsions

five. Particle length reduction

6. Nanosuspensions

7. Co-crystal

eight. stable dispersion (amorphous)

nine. Liposomes

10. Complexation

every drug delivery technique has its benefits and drawbacks, but choosing the most appropriate drug shipping systems remains accomplished through a aggregate of science and art. regular best and healing overall performance all through scale-up and storage in selecting a appropriate solubilization technique have to be taken into consideration for drug improvement and next regulatory assessment.

**pH Adjustment and Salt Formation**

it's miles well known that the aqueous solubility of acidic, primary, and amphoteric capsules can be impacted through dissolution media pH values [11,12,13]. whilst the pH cost of the medium is close to or higher than the pKa of an acidic drug, the drug’s solubility will increase extensively because the pH price will increase; when the pH value of the medium is close to or higher than the pKb of a simple drug, the drug’s solubility will lower considerably because the pH value will increase. For amphoteric drugs which can react as an acid as well as a base, including sulfadimethoxine and cefadroxil, the aqueous solubility might be better at either acidic or primary media.

similarly to liquid components wherein the pH value can be at once adjusted to acquire preferred solubility, it's also a not unusual exercise to enhance drug dissolution rate with the aid of adjusting microenvironment pH in strong dosage bureaucracy particularly in MR formulations. for instance, in an osmotic pump-primarily based MR method, the pH cost may be constant via selecting appropriate excipients, because no different ions besides water can input the osmotic pump after oral management. therefore, adjusting the pH in the osmotic pump-based totally

system can be very beneficial for keeping drug solubility and/or balance. but, one of the predominant disadvantages of using pH adjustment is that the solubilized drug may precipitate out with environmental pH changes in the human GI tract, or upon injection. as an instance, sodium salts of warfarin and phenytoin can also convert returned to insoluble acids at some stage in dissolution in acidic belly surroundings [14,15]. consequently, the pH stability profile of a drug ought to be evaluated before the usage of the pH adjustment method.

For ionizable compounds with terrible water solubility, forming salts is common exercise within the pharmaceutical industry and Morris et al. [16] have proposed an included technique to the selection of the finest salt form for a new drug candidate. The handbook of Pharmaceutical Salts [17]. has summarized all typically used counterions in forming salts with unfastened acids or unfastened base, in addition to their related homes. without cost acids, the counterions utilized in salt formation include, but are not restrained to, sodium, potassium, calcium, and zinc. without cost bases, the counterions utilized in salt formation encompass, but aren't restricted to, phosphate, hydrochloride, malonate, mesylate, succinate, and acetate. even though salt formation can enhance the dissolution price of medicine with terrible water solubility, it's miles vital to notice that the salt does not vital trade their pH solubility profiles. The effect of counterions on pH solubility profiles can be complicated, and the negative effect of the counterion in dissolution media cannot be unnoticed [18]

**Co-Solvents**

Use of co-solvent is one of the only and most not unusual processes in solubilizing pills with poor water solubility. The maximum usually used co-solvents in oral and parenteral formulation designs are propylene glycol (PPG), polyethylene glycol (PEG), ethanol, and glycerin. Yalkowsky et al. have proposed one of the best and most beneficial equations to predict drug solubility in co-solvent systems:

log Sm ¼ flog Sc þ ð Þ 1−f logSw

in which Sm is the solubility of the drug within the binary mixture, f is the quantity fraction of the co-solvent, Sc is the solubility of the drug inside the natural co-solvent, and Sw is the solubility of the drug in water. Trivedi [20] has summarized commercially to be had oral and injectable drug products the usage of co-solvents in his comprehensive evaluation of drug solubilization the usage of the co-solvent approach. Commercially available solubilized oral merchandise encompass, however are not restricted to, phenobarbital solubilized via ethanol andetoposide by PEG-four hundred and glycerin, in addition to rapamycin and ester derivatives through ethanol. One foremost downside is precipitation on dilution. while a formulation is diluted with blood or different aqueous media, the concentrations of each the drug and the co-solvent may be reduced to the equal quantity. If the drug attention in the diluted media is higher than the drug solubility within the new medium, the drug can also end up supersaturated in the diluted medium and even precipitate out. Such precipitation might also bring about therapeutic failure, and if the precipitation takes place in IV infusion, may additionally bring about tissue harm, or maybe organ failure. other barriers consist of toxicity and the allowable maximum quantity that may be used effectively. as an example, PEG will have poisonous effects at the kidney [21]. word that the necessities with the aid of one-of-a-kind regulatory organizations can be specific.

**Micelles**

Drug solubilization the usage of surfactants above the vital micelle awareness (CMC) has been broadly used for boosting bioavailability of drugs with bad water solubility [22–24]. historically used pharmaceutical surfactants can be categorized into four businesses: non-ionic, anionic, cationic, and zwitterionic surfactants. in addition to conventional surfactants, consisting of sodium lauryl sulfate, quaternary ammonium, and polysorbates, diblock polymers and triblock polymers have additionally been designed and used for polymeric micelle-primarily based drug transport. Micelles, an mixture of surfactant molecules dispersed in a liquid colloid, shape most effective while the surfactant attention is better than the CMC, and the medium temperature is also greater than the vital micelle temperature. As in a micelle, the hydrophilic head of a surfactant molecule is uncovered to the aqueous answer, even as its hydrophobic tail stays within the micelle. The hydrophobic part of micelles can have interaction with the hydrophobic part of poorly soluble capsules, and solubilize them.

The water-insoluble drug will exist in both the aqueous segment and micellar phase and reach equilibrium among the two phases. there are many factors contributing to micellization and micellar solubilization, together with temperature, pH value, electrolytes and ionic electricity, nature and concentration of surfactant and solute, as well as other ingredients. at the same time as improving solubilization capability, surfactants can also reason toxicity or even disrupt the membrane shape. because the toxicity of a surfactant is directly related to its concentration, the surfactant toxicity has to be taken into consideration for the duration of drug development. In self-micellizing solid dispersion (SMSD) structures, surfactants or amphiphilic block copolymers were used to shape micelles in aqueous media to solubilize tablets with poor water solubility and to prevent drug precipitation at some point of dissolution process [25,26]. Many tablets with negative water solubility were effectively advanced and commercialized using micellar solubilization, along with paclitaxel injection and cyclosporine injection, as well as griseofulvin-PEG-dispersion.

further to solubilization for water-insoluble tablets, micelles have additionally been explored to reap passive focused on, stimuli sensitivity, ligand-mediated focused on, intracellular shipping of micelles, and intracellular trafficking [27]. Like many superior drug transport structures, centre and stimuli sensitive micelles have not been widely used in real drug development due to various reasons. amongst them, the conversation gap between clinical needs and drug transport research has surely restricted the application of superior drug delivery in resolving practical demanding situations confronted by using pharmaceutical industry.

**Emulsions and Microemulsions**

As lipid-primarily based drug delivery systems, emulsions and microemulsions have been extensively studied and applied for drug solubilization [28,29]. An emulsion is a combination of immiscible beverages (commonly, water and oil) stabilized through an emulsifier. Microemulsions (oil/water, water/oil) are clear, strong, isotropic liquid combinations of oil/lipids, water, emulsifiers (surfactants), and/or co-solvents (e.g., ethanol, PPG, PEG). The surfactant molecules may additionally shape a monolayer at the interface between the oil and water, with the hydrophobic tails of the surfactant molecules dissolved in the oil phase and the hydrophilic head groups within the aqueous phase, and stabilize the emulsion by decreasing the interfacial tension among the oil and aqueous phase. the various a couple of blessings of emulsions and microemulsions, of them must be stated in particular: (1) the ability to keep away from precipitation upon dilution, and (2) the blended techniques with other formula strategies. similarly to traditional emulsions and microemulsions, Gao et al. [30–32] have developed supersaturated self-emulsifying drug shipping device (S-SEDDS) and feature substantially improved oral absorption in comparison to the traditional SEDDS method. SSEDDS represents a new solid method technique which contains reduced amount of a surfactant and powerful polymeric crystallization inhibitor (like hydroxypropyl methycellulose [HPMC] and polyvinylpyrrolidone [PVP]) to generate and maintain an in vivo supersaturated drug solution for tablets with terrible water solubility. they have got correctly implemented S-SEDDS for multiple water-insoluble capsules and have carried out huge improvement of in vivo bioavailability in each animal and humans. There are not many industrial drug products using emulsions or microemulsions due to bodily and chemical stability demanding situations. however, inside the pharmaceutical industry, emulsions and microemulsions are generally used during the early improvement degree for bioavailability enhancement, specially for animal toxicity studies, on the grounds that emulsion and microemulsions can help deliver the maximum quantity of drug to acquire the highest bioavailability.

**Particle size reduction and Nanosuspensions**

Particle size discount is normally used to reap faster dissolution and higher bioavailability. based totally on Fick’s first regulation of diffusion, the drug launch charge is determined through the drug release floor area, the thickness of transport barrier, and the attention difference between drug donor and receptor, this is, the difference among the drug dosage floor and the dissolution bulk media. within the pharmaceutical industry, to decorate drug dissolution quotes, water-insoluble tablets are usually micronized to ∼10 μm or less for oral dosage bureaucracy. It should be mentioned that reducing particle length will no longer most effective increase surface area but additionally affect drug substance solubility via changing surface loose power. For particles large than a few microns, the solubility (additionally known as macroscopic solubility) will now not alternate because the interfacial power change is negligible. while particle length is smaller than one hundred nm (i.e., nanoparticles), the high particle surface unfastened power will make contributions to a better solubility (additionally called microscopic solubility). usual, particle length reduction to less than 1 μm will beautify drug dissolution quotes by means of larger floor areas and/or better solubility.

The methods for particle size reduction include, however aren't constrained to, fluid power milling (dry milling), ball milling, media milling (stirred ball milling), and micro fluidization (excessive stress). The challenges of nanosuspension development stem from no longer only reproducible scale-up and production system however additionally capability stability issues like surface vicinity increase and particle aggregation [33]. lists the nanotechnologies and a number of the correctly marketed tablets the usage of those technology. despite the fact that nanotechnology has been used effectively to improve dissolution and oral bioavailability, considering the price concerned in overcoming the demanding situations of processing and balance as compared to other methods for drug solubilization (e.g., cosolvents), nanotechnology is not the most broadly used for drug solubilization. in addition to solubilization, nanotechnology has attracted more and more attention in targeted drug transport and one of the most a hit tablets is Abraxane™ (protein bound nanoparticle components of paclitaxel) [33]. even though the complexity of nanoparticles have posed challenges in placing regulatory requirements, FDA has posted the draft BE steering for Abraxane™ [34], which has endorsed each in vivo bioequivalence have a look at with pharmacokinetic (PK) endpoints and in vitro particle size distribution.

**Co-Crystals and Amorphous solid Dispersion**

modifying the solid state by means of co-crystal or amorphous stable dispersion can also beautify drug dissolution. In April 2013, FDA published the guidance for industry, B Regulatory type of Pharmaceutical Co-Crystals [33]. in which co-crystals are surely described as B solids that are crystalline materials composed of or extra molecules inside the identical crystal lattice. among multiple blessings, co-crystals can gain better oral bioavailability through improved dissolution price and permit formulations to be manufactured via conventional granulation methods which might be extra environmentally friendly than stable dispersion. however, the risk of changing to lose drug mainly at slurry can't be underestimated. because the final decade, there were many drug development research primarily based on co-crystal technique [36– 39]. as an instance, Novartis’ LCZ696, an investigational mixture drug including two antihypertensives (blood stress-decreasing tablets), valsartan and sacubitril [40], granted precedence evaluate designation by way of the FDA [41], has been accepted by using FDA to lessen hazard of cardiovascular death and coronary heart failure hospitalization [42].

In amorphous solid dispersion(s), drug molecules trade from crystalline shape to amorphous shape, and the trade reasons their loose electricity stage to growth substantially [43,44]. The better unfastened power level as well as improved surface vicinity contributes to the enhanced dissolution price of amorphous solid dispersion drug merchandise. normal polymers used in amorphous solid dispersion guidance are PEG, HPMC, PVP, hypromellose acetate succinate (HPMCAS), and now and again two or extra polymers may be used collectively within the amorphous solid dispersion. The marketed strong dispersion capsules include, however are not constrained to, griseofulvin, nabilone, itraconazole, tacrolimus, and lopinavir/ritonavir. Roche’s vemurafenib, a nearly insoluble drug, has been efficiently advanced the use of an amorphous polymer stabilized stable dispersion prepared with the aid of a solvent-managed co-precipitation system [45]. in the course of garage of amorphous stable dispersions, drug won't simply recrystallize from the amorphous state but also face more/in addition chemical balance challenges due to the better unfastened electricity. further to the bodily and chemical stability challenges all through garage, drug may additionally precipitate out from answer throughout dissolution because dissolved drug usually exists as supersaturated answer. in spite of the extremely good potential for reinforcing bioavailability using strong dispersion, the/its industrial application is confined and just a few products have been marketed so far. To make certain consistent pleasant and scientific performance, it's miles important to deepen the know-how of amorphous strong dispersions, specifically the impact of high-quality trade on therapeutic performance.

**Liposomes**

Liposomal transport, an exciting drug shipping device specifically for tablets with bad water solubility, together with anticancer and anti-HIV compounds, has been broadly studied. Liposomes are bilayer phospholipid structures that convey capsules by using entrapping them in tiny vesicles and might offer controlled release (CR) delivery in addition to centre transport. typical routes of management for liposome merchandise are IV, intramuscular (IM), and subcutaneous (SC). however, compared to different drug delivery structures, fewer pills have been correctly developed and marketed using liposomal drug transport structures.

a number of the demanding situations in growing liposomal transport systems are the problem of preserving pills in the liposomes, the rapid clearance of liposomes via the frame’s mononuclear phagocyte gadget, the transport to intracellular sites, and scale-up issues [46]. in spite of these demanding situations, there are a number of efficiently marketed drug products using liposomes. as an instance, incorporating ldl cholesterol or sphingomyelin inside the phospholipid bilayer helped to keep the drug inside the liposomes [47,48]. Vincristine, a broadly used anticancer drug, has excessive neurotoxicity and has fast clearance using the traditional transport system. The sphingomyelin/ldl cholesterol liposomes of Marqibo® (vincristine sulfate liposome injection) provided slower clearance to beautify exposure to the tumor cells and obtained extended approval by the FDA in 2012 [49]. within the case of amphotericin b, a pretty renal poisonous drug, incorporation of cholesterol within the liposomal transport machine significantly stepped forward tolerability via stabilizing the drug within the liposomes [50]. Attaching PEG to the liposomes (PEGylation) will increase the flow 1/2-life of the liposomes [51]. Antibody-focused liposomes bode nicely for focused remedy, although the shipping system involves tedious manipulations [52,53]. Liposomal shipping structures can be designed to be warmness-sensitive, pH-sensitive, photosensitive, enzyme-prompted, or maybe magnetically responsive to supply the drug to a goal organ or tumor [46]. desk II presents a list of some of the advertised merchandise with a quick description of the liposomal technologies which might be used. There is a lot of opportunity for growing a hit drug products with effective scientific consequences, specially for anticancer pills.

For each nano particles and liposomes, their particle size distribution may impact in vivo drug performance thru no longer best drug release but also drug deposition on focused tissue which has no longer been fully understood. To in addition understand the impact of particle length distribution on in vivo drug overall performance, multiple questions must be addressed, together with the way to degree particle length specifically the ones small particles, dimension reproducibility, batch reproducibility, the relationship among particle size distribution and drug release, in addition to the connection between particle size distribution and drug deposition.

**Complexations**

Cyclodextrins (CDs) are commonly used excipients for solubility improving via forming complexation with pills with negative aqueous solubility [54]. α-, β-, and γ-CDs, which respectively consist of six, seven, and 8 D-glucose gadgets, had been utilized in pharmaceutical packages. The cavity of CDs is fantastically apolar, where capsules with poor water solubility can shape complexation with CDs. The inner hollow space diameters are about 5.7, 7.8, and nine.five Å for α-, β-, and γ–CDs, respectively. similarly to being a solubilization drug transport device, complexation has additionally been used to growth drug balance, lessen inflammation to the human GI tract [55], and masks unpleasant flavor [US 20030215503 A1].

There are numerous blessings in using CD complexation for solubility enhancement [54]. first off, the dissociation among complexing agent and drug could be very fast. Secondly, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and sulfobutyl ether-β-cyclodextrin (SBE-β-CD) are much less toxic while as compared to other solubilizing agents along with surfactants and cosolvents. Thirdly, because maximum of the complexation are 1:1 complexes, dilution of the complicated will no longer result in a supersaturated answer for water-insoluble capsules; as a consequence, precipitation upon dilution is not a concern as generally

determined in different solubilization methods which includes amorphous solid dispersion, co-solvent, and pH adjustment. ultimately, complexation may be mixed with different processes which include solid dispersion and pH adjustment to enhance the bioavailability of water-insoluble drugs

As predicted, there also are dangers the usage of complexation [54]. To shape complexes with complexing agents, drugs with bad water solubility sometimes ought to first be dissolved inside the medium. For compounds with very constrained solubility, the solubility enhancement could be very restricted by taking the binding constants of complexes into attention. the second one quandary is that for the complexes of Ap kind that have fashioned better order complexes [53], dilution of a machine might also still bring about precipitation. other boundaries are the potential toxicity, regulatory issues springing up from the toxicity, and fine manage issues associated with the presence of the ligand, which may also upload trouble and cost to the improvement process. lastly, in comparison with other approaches, the complexation efficiency is often as an alternative low, consequently both tremendously big amount of CDs are normally required to reap ideal solubilization effect, or a mixture with different drug shipping systems is favored.

As reported via Cyclo Lab, a CD-manufacturing organization, within the February 2013 trouble of the cyclodextrin information, there has been a total of fourty nine marketed CD pharmaceutical merchandise across the world, normally in India, Europe, and Japan, with some inside the u.s.a. most of the fourty nine products, fourty five used β-CD and its derivatives. the medicine approved within the usa and around the world using SBE-β-CD (Captisol®) encompass, but aren't limited to, voriconazole and ziprasidone mesylate via Pfizer, aripiprazole with the aid of Bristol-Myers Squibb, and amiodarone hydrochloride via Baxter. the medicine permitted in the u.s.a. and round the sector utilising HP-β-CD encompass, but aren't constrained to, itraconazole by means of Janssen, indomethacin by way of Chauvin, and mitomycin through Novartis [55].

**Conclusion:**Drug delivery is not merely a means of transporting therapeutic agents but a critical determinant of a drug’s clinical success. The evolution of drug delivery technologies has significantly expanded the scope of therapeutic interventions, enabling higher precision, improved safety, and greater patient-centricity. This review has illustrated that each delivery strategy—whether it is enhancing solubility through nanotechnology, increasing permeability via prodrug design, modulating drug release profiles, or targeting specific tissues using advanced carriers—plays a vital role in addressing core pharmacological challenges.

The integration of pharmacokinetics with formulation science allows for a more refined control over drug absorption, distribution, metabolism, and excretion, ultimately leading to better therapeutic indices. Furthermore, targeted delivery systems have revolutionized treatment paradigms, particularly in oncology, by reducing systemic toxicity and increasing local drug concentration at disease sites.

As the pharmaceutical landscape evolves with biologics, gene therapies, and patient-specific interventions, drug delivery systems will continue to serve as a foundational pillar of innovation. The future lies in smart, responsive systems that adapt in real time to patient physiology, in conjunction with digital health platforms that ensure adherence and optimize dosing.

In conclusion, a holistic, multidisciplinary approach to drug delivery—supported by regulatory compliance, manufacturing scalability, and translational research—can transform the potential of pharmacological therapies into real-world clinical impact. By continuing to innovate across all stages of development, drug delivery science will remain essential to enhancing therapeutic performance, improving health outcomes, and fulfilling the promise of personalized medicine.

**References:**

1. Drug delivery . Wikipedia. Available from: <http://en.wikipedia.org/wiki/Drug_delivery>
2. Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Control Release. 2014;190:15–28.
3. Dawidczyk CM, Russell LM, Searson PC. State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines. J Control Release. 2014;187:133–44.
4. U.S. FDA. Guidance for industry and review staff: target product profile—a strategic development process tool. 2007.
5. Advanced delivery devices - wearable bolus injectors - a new class of patient-friendly drug delivery systems. 2014.
6. Technology Catalysts. Next-generation self-administered drug-device combinations: new technologies and business opportunities [Internet]. Available from: <http://www.technology-catalysts.com/reports_services/ddc.asp>
7. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.
8. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002;19(7):921–5.
9. Yu LX, Amidon GL. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev. 1996;19(3):359–76.
10. Shi Y, Porter WW, Peng S, Wagner LE, Zuo J. Recent advances in intravenous delivery of poorly water-soluble compounds. Expert Opin Drug Deliv. 2009;6(12):1261–82.
11. Shoghi E, Sohrabi A, Fasihi M, Torshizi M, Tabrizchi M. Solubility–pH profiles of some acidic, basic and amphoteric drugs. Eur J Pharm Sci. 2013;48:291–300.
12. Voelgyi G, Pál S, Berkesi O, Keresztury G. Study of pH-dependent solubility of organic bases. Anal Chim Acta. 2010;673(1):40–6.
13. Chemsilico. The relationship between drug aqueous solubility and pH values [Internet]. Available from: http://www.chemsilico.com/CS\_prWS/WSintro.html
14. Serajuddin ATM, Jarowski CI. Influence of pH on release of phenytoin sodium from slow-release dosage forms. J Pharm Sci. 1993;82(3):306–10.
15. Walker JE, Eichenbaum G, Bell R. In vivo and in vitro availability of commercial warfarin tablets. J Pharm Sci. 1971;60(5):666–77.
16. Morris KR, Fakes MG, Thakur AB, Newman AW, Bugay DE, Sisco JM, et al. An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm. 1994;105(3):209–17.
17. Li S, Yalkowsky SH, Haskell RJ. Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug. J Pharm Sci. 2005;94(10):2224–31.
18. Yalkowsky SH, Roseman TJ. Solubilization of drugs by cosolvents. Drugs Pharm Sci. 1981;12:91–134.
19. Trivedi JS. Solubilization using cosolvent approach. In: Water-insoluble drug formulation. 2nd ed. 2008. p.161–94.
20. WHO. Ethylene glycol: human health aspects. 2002.
21. Florence AT. Drug solubilization in surfactant systems. Drugs Pharm Sci. 1981;12:15–89.
22. Liu R, Dannenfelser R-M, Li S. Micellization and drug solubility enhancement. In: Water-insoluble drug formulation. 2nd ed. 2008. p.255–306.
23. Liu R, Forrest ML, Kwon GS. Micellization and drug solubility enhancement Part II: polymeric micelles. In: Water-insoluble drug formulation. 2nd ed. 2008. p.307–74.
24. Frank KJ, Boeck G, Brueckner L, McCreath G, Schaefer UF, Lehr CM. Mechanism behind increased permeation rate of a poorly soluble drug from aqueous dispersions of an amorphous solid dispersion. J Pharm Sci. 2014;103(6):1779–86.
25. Onoue S, Kojima T, Yamada S. Self-micellizing solid dispersion of cyclosporine A with improved dissolution and oral bioavailability. Eur J Pharm Sci. 2014;62:16–22.
26. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24(1):1–16.
27. Cannon JB, Shi Y, Gupta P. Emulsions, microemulsions, and lipid-based drug delivery systems for drug solubilization and delivery—part I: parenteral applications. In: Water-insoluble drug formulation. 2nd ed. 2008. p.195–226.
28. Cannon JB, Long MA. Emulsions, microemulsions, and lipid-based drug delivery systems for drug solubilization and delivery—part II: oral applications. In: Water-insoluble drug formulation. 2nd ed. 2008. p.227–54.
29. Gao P. Fundamental concept, design and development of supersaturatable S-SEDDS: a case study. Bull Tech Gattefosse. 2011;104:51–60.
30. Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W, et al. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J Pharm Sci. 2009;98(2):516–28.
31. Shi Y, Zhu H, Liu L, Zhang J. Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption. Mol Pharm. 2010;7(5):1458–65.
32. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282–95.
33. Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007;59(7):617–30.
34. Chaudhari PK, Dudhat M, Thosar M. Co-crystallization: a novel approach for enhancing drug properties. Inventig Impact Pharm Tech. 2012;2:58–61.
35. Hoffman M, Lindeman JA. Co-crystals: commercial opportunities and patent considerations. RSC Drug Discov Ser. 2012;16:3 18–29.
36. Sekhon BS. Drug–drug co-crystals. Daru J Pharm Sci. 2012;20:45.
37. Gradman AH. LCZ696: the next step in improving RAS inhibition? Curr Hypertens Rep. 2015;17(5):1–9.
38. Novartis. Novartis’ heart failure medicine LCZ696 granted FDA priority review. 2015.
39. Novartis. Novartis’ new heart failure medicine LCZ696, now called Entresto™, approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization [Internet]. 2015. Available from: <https://www.novartis.com/news/media-releases/novartis-newheart-failure-medicine-lcz696-now-called-entrestotm-approvedfda>
40. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999;88(10):1058–66.
41. Vasanthavada M, Tong WQ, Serajuddin ATM. Development of solid dispersion for poorly water-soluble drugs. In: Water-insoluble drug formulation. 2nd ed. 2008. p.499–529.
42. Shah N, Sandhu H, Choi DS, Chokshi H, Malick AW. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled co-precipitation process. J Pharm Sci. 2013;102(3):967–81.
43. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
44. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J. 1980;186(2):591–8.
45. Allen TM, Hansen C, Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta Biomembr. 1989;981(1):27–35.
46. Silverman JA, Deitcher SR. Marqibo (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71(3):555–64.
47. Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res. 1993;3(3):429–50.
48. Kharia AA, Hiremath SN, Singhai AK, Omray LK. Formulation strategy for low absorption window antihypertensive agent. Res J Pharm Technol. 2010;3(1):113–7.
49. Rotman M, Welling MM, Bunschoten A, van der Graaf LM, Hoozemans JJ, van Buchem MA, et al. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer’s disease. J Control Release. 2015;203:40–50.
50. Park JW, Kirpotin DB, Hong K, Zalipsky S, Li WL, Carter P, et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A. 1995;92(5):1327–31.
51. Tong WQ, Wen H. Applications of complexation in the formulation of insoluble compounds. In: Water-insoluble drug formulation. 2nd ed. 2008. p.133–59.
52. Szekely-Szentmiklosi B, Tokes B. Characterization and molecular modelling of cyclodextrin/fluoroquinolone inclusion complexes. Acta Med Marisiensis. 2011;57(2):116–20.
53. Zoeller T, Dressman JB, Klein S. Application of a ternary HPβ-CD-complex approach to improve the dissolution performance of a poorly soluble weak acid under biorelevant conditions. Int J Pharm. 2012;430(1–2):176–83.
54. Sistla A, Kertelj A, Shenoy N. Development of an intravenous formulation of SU010382 (prodrug of SU5416, an antiangiogenesis agent). PDA J Pharm Sci Technol. 2008;62(3):200–10.
55. Badr-Eldin SM, Elkheshen SA, Ghorab MM. Inclusion complexes of tadalafil with natural and chemically modified β-cyclodextrins. I: Preparation and in-vitro evaluation. Eur J Pharm Biopharm. 2008;70(3):819–27.